stooocks.com

Understand any stock in simple English

Ion Beam Applications SA

Belgium ยท Euronext Brussels:ย IBAB.BR ยท Market cap: ยท P/E: ยท P/S:

IBA builds the machines and drugs used to treat cancer, especially proton therapy systems and radiopharmaceuticals.

IBA is a Belgian company that makes the heavy hardware and the radioactive drugs used in cancer care. Its biggest claim to fame is proton therapy: a way of firing a beam of protons into a tumor so that most of the energy lands on the cancer and spares the healthy tissue around it. Hospitals buy these systems because they let doctors treat tumors near delicate places โ€” the brain, the spine, the eyes of children โ€” with less collateral damage than conventional X-ray radiation.

A proton therapy center is a major construction project, not an appliance. It needs a building with thick shielding, a particle accelerator called a cyclotron, beam lines, and rooms where patients lie still while a machine rotates around them. IBA designs and installs the whole thing, then keeps it running with service contracts and upgrades. That means the money is lumpy โ€” a handful of large orders can swing a year โ€” and the sales cycle is long, because hospitals raise funds, win permits, and plan buildings before anything gets built. The flip side is that once IBA is inside a hospital, maintenance and upgrades keep the relationship going for years. The other big leg is radiopharmaceuticals. IBA makes radioactive tracers used in medical scans and, more importantly, in therapy โ€” drugs that carry a tiny radioactive payload directly to cancer cells. The company also has a dosimetry business that helps hospitals measure and verify radiation doses, so treatments are accurate and safe. The competition is real. Varian Medical Systems is the dominant name in conventional radiation equipment (though it is now part of Siemens Healthineers), and Elekta sells both radiation machines and, through its partnership with RaySearch, software that runs them; both loom large in hospital purchasing decisions. In proton therapy specifically, IBA's main rival is Hitachi, which has installed systems in the United States and Japan. What keeps IBA in the game is that it has been doing this longer than almost anyone โ€” it was founded in 1986 by Yves Jongen, an engineer who started with cyclotron technology at a university lab in Louvain-la-Neuve โ€” and it can offer hospitals a complete package: the machine, the building design, the software, the drugs, and the service crew.


The business is not a smooth compounder. Proton therapy orders are big and infrequent, so revenue can jump or stall depending on timing, and the company has had years where profits disappointed investors. It also carries debt and has gone through restructuring. Still, the underlying demand is strong: cancer cases are rising as populations age, and proton therapy is moving from a rare luxury toward a more standard option as more centers open. IBA is a bet on that shift โ€” a company that sells expensive, lifesaving machines to hospitals and then earns steady fees keeping them alive.

Saved answer ยท last researched 17 Nov 2026